Biotechnology News and Research

RSS

Phase III study suggests CYCLOSET tablets improve glycemic control

Santarus, Inc. and VeroScience LLC today announced that analyses of 379-patient subset data from a 3,070-patient Phase III safety study conducted with CYCLOSET (bromocriptine mesylate) tablets suggested that CYCLOSET as an add-on to oral antidiabetes drugs produced improvements in glycemic control irrespective of baseline duration of disease.

4 Nov 2010

Lentigen awarded $1.23M grant under Patient Protection and Affordable Care Act

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery products, announced today that it will receive $1,235,306 in cash grants from the U.S. Government under the Patient Protection and Affordable Care Act.

4 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

Coronado completes series of private financings

Coronado Biosciences, Inc., a privately held company engaged in innovative oncology drug development, announced completion of a series of private financings in 2010, resulting in aggregate gross proceeds to the Company of approximately $21.6 million.

4 Nov 2010

Bolder BioTechnology receives $1.2 million in Qualifying Therapeutic Discovery Project Grants

Bolder BioTechnology, Inc. today announced that it has been awarded a total of $1.2 million in Qualifying Therapeutic Discovery Project Grants. Grants were awarded for qualified investments under the Qualifying Therapeutic Discovery Project Tax Credit Program, which authorized up to $1 billion in tax credits or grants to biopharmaceutical companies with 250 or fewer employees.

4 Nov 2010

PIKAMAB awarded QTDP program grants to advance development of theragnostic products

PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC Therasight and Lupus Therasight. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.

4 Nov 2010

Affymetrix to contribute genotyping data to 1000 Genomes Project

Affymetrix, Inc. today announced that it will contribute genotyping data for a large set of validated rare and common genomic variants to the 1000 Genomes Project. This powerful data consists of genotyping information from more than 2 million single nucleotide polymorphisms (SNPs), and insertions/deletions (indels), many of which were not previously available from any source.

4 Nov 2010

OPKO acquires major share in Fabrus

OPKO Health, Inc. announced that it has made an investment in Fabrus, LLC, a privately held early stage biotechnology company with next generation therapeutic antibody drug discovery and development capabilities. In exchange for the Company's investment, the Company acquired approximately 13% of Fabrus' outstanding membership interests on a fully diluted basis.

4 Nov 2010

pSivida awarded $489,000 grant under IRS Qualifying Therapeutic Discovery Project

pSivida Corp., a leader in the development of sustained release drug delivery products for the treatment of back-of-the-eye disease including the product candidate Iluvien™ for the treatment of Diabetic Macular Edema, today announced that it has been awarded two grants totaling $489,000 under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grants were awarded to pSivida to help fund further research on new generations of the company's drug delivery technologies targeting ophthalmic diseases.

4 Nov 2010

BioCurex files patent for synthetic peptide in RECAF test

BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.

4 Nov 2010

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals, Inc. a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has been awarded grants totaling $977,900 under the Qualifying Therapeutic Discovery Project (QTDP) Program administered under section 48D of the Internal Revenue Code.

4 Nov 2010

Single injection of morphine to fight persistent pain reduces testosterone level: Research

A single injection of morphine to fight persistent pain in male rats is able to strongly reduce the hormone testosterone in the brain and plasma, according to a new paper published in Molecular Pain.

4 Nov 2010

Spherix subsidiary awarded $469,479 grant under Patient Protection and Affordable Care Act

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its subsidiary, Biospherics Incorporated, has been awarded $469,479 under HR: 3590 – Patient Protection and Affordable Care Act in immediately available funds.

4 Nov 2010

Biogen Idec and Cardiokine terminate lixivaptan collaboration

Biogen Idec and Cardiokine, Inc. today announced that they have agreed to dissolve their collaboration on lixivaptan. The termination of the collaboration, which began in 2007, triggers the return of all rights to lixivaptan to Cardiokine.

4 Nov 2010

PolyMedix receives $488,958 grants under QTDP program

PolyMedix, Inc. a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, announced today that it has been awarded two cash grants totaling $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

4 Nov 2010

Idaho seeks FDA marketing clearance for FilmArray Respiratory Panel

Idaho Technology, Inc. (ITI) announced today that it has filed a submission with the U.S. Food and Drug Administration for 510(k) clearance to market its FilmArray Respiratory Panel (RP) as an in vitro diagnostic product for patients with symptoms of upper respiratory tract infection.

4 Nov 2010

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.

3 Nov 2010

Harvard Bioscience third quarter revenue increases 26.0% to $26.5 million

Harvard Bioscience, Inc. a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial highlights for the three and nine months ended September 30, 2010.

From Harvard Bioscience 3 Nov 2010

QLT third quarter sales decreases 12.9% to $20.5 million

QLT Inc. today reported financial results for the third quarter ended September 30, 2010. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

3 Nov 2010

Deloitte releases new report on innovative strategies for oncology drug development

Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion in oncology drugs while transforming the medical outlook for many cancer patients.

3 Nov 2010